Successful tapering of dupilumab in atopic dermatitis patients with low disease activity: a large pragmatic daily practice study from the BioDay registry.
Lotte S SpekhorstCeleste M BoesjesLaura LomanNicolaas P A ZuithoffDaphne S BakkerEsmé KamphuisMarijke KamsteegInge HaeckAlbert J OostingPaula P M van LumigAnneke M T van Lynden-van NesRon A TupkerAnnebeth FlintermanFloor M GarritsenWouter R H TouwslagerMarjolein S de Bruin-WellerMarie-Louise A SchuttelaarMarlies de GraafPublished in: The British journal of dermatology (2023)
This study showed successful tapering of dupilumab in 83.3% of AD patients who attempted tapering while maintaining controlled disease and with the majority using Q3W/Q4W. Interval prolongation can be both beneficial for the patient and from a socio-economic perspective.